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Background: The molecular basis underlying activation of the fetal gene program during development of left ventricular hypertrophy (LVH) is 
poorly understood. Epigenetics is the study of non-genetic code modifications that alter gene expression. No studies have assessed global epigenetic 
changes in LVH. We studied DNA methylation and epigenetic modifying gene expression profiles between spontaneously hypertensive rats (SHR) and 
age-matched controls (WKY) to test the hypothesis that there are global epigenetic changes with LVH.
Methods: SHR and WKY rats (n=4) were euthanized at 2 and 10 months of age after blood pressure (BP) measurement and echocardiography 
were performed. Nucleic acids were extracted from LV tissue. Global DNA methylation levels were assessed by HPLC/mass spectroscopy at each time 
point. RNA expression profiling was performed for 168 epigenetic modifying genes using RT2 Profiler RT-PCR kits (SA Biosciences; n=3) at 2 and 10 
months of age.
Results: SHRs had higher BP at 2 months and developed LVH by 10 months compared to WKY (p<0.05). Global DNA methylation was not 
significantly different between 2-month old WKY and SHR (1.69±0.02% vs. 1.78±0.06%, p=0.055) but was significantly higher in SHR at 10 
months (1.93±0.06% vs. 2.06±0.04%, p=0.03). At 2 months, epigenetic modifying gene expression profiles were similar between WKY and SHR (6 
genes ≥1.5 fold change, p<0.05). Profiles were also similar between 2- and 10-month WKYs (5 genes ≥1.5 fold change, p<0.05). There was global 
downregulation of epigenetic modifying gene expression in 10-month compared to 2-month SHRs (47 genes ≥1.5 fold change, p<0.05) as well as in 
10-month WKYs compared to 10-month SHRs (19 genes ≥1.5 fold change, p<0.05). Epigenetic modifying genes were mostly downregulated in SHRs 
with a minority of genes overexpressed compared to controls. No predominance of any particular gene class was found.
Conclusions: These new data suggest that DNA methylation is increased concomitantly with altered expression of epigenetic modifiers during the 
development of LVH. Modification of the cellular epigenetic machinery is a previously unexplored area of cardiac biology and a potential target for 
therapeutic intervention.
